title: Chromosomal instability predicts metastatic disease in patients with insulinomas.
abstract: Endocrine pancreatic tumors (EPTs) comprise a highly heterogeneous group of tumors with different clinical behavior and genetic makeup. Insulinomas represent the predominant syndromic subtype of EPTs. The metastatic potential of insulinomas can frequently not be predicted using histopathological criteria, and also molecular markers indicating malignant progression are unreliable because of the small number of cases per subtype studied so far. For the identification of reliable indicators of metastatic disease, we investigated 62 sporadic insulinomas (44 benign and 18 tumors with metastases) by means of comparative genomic hybridization (CGH). In addition, the role of MEN1 (multiple endocrine neoplasia type 1) gene mutations was determined to assess specific chromosomal alterations associated with dysfunction of this endocrine tumor-related tumor suppressor gene. Only one case with a somatic MEN1 mutation was identified (1527del7bp), indicating that the MEN1 gene plays a minor pathogenic role in sporadic insulinomas. CGH analysis revealed that the total number of aberrations per tumor differs strongly between the benign and the malignant group (4.2 vs 14.1; P<0.0001). Furthermore, chromosome 9q gain was found to be the most frequent aberration in both benign and malignant insulinomas, whereas chromosome 6q losses and 12q, 14q and 17pq gains are strongly associated with metastatic disease. Our study shows that chromosomal instability, as defined by > or =5 gains together with > or =5 losses, or total number of gains and losses > or =8, rather than parameters such as tumor size and proliferation index, is the most powerful indicator for the development of metastatic disease in patients with sporadic insulinoma.
authors.affiliation: Department of Molecular Cell Biology Box 17, Research Institute for Growth and Development, University of Maastricht, PO Box 616, 6200 MD, Maastricht, The Netherlands. Y.Jonkers@MOLCELB.unimaas.nl
authors.forename: Y M H
authors.initials: YM
authors.lastname: Jonkers
authors.forename: S M H
authors.initials: SM
authors.lastname: Claessen
authors.forename: A
authors.initials: A
authors.lastname: Perren
authors.forename: S
authors.initials: S
authors.lastname: Schmid
authors.forename: P
authors.initials: P
authors.lastname: Komminoth
authors.forename: A A
authors.initials: AA
authors.lastname: Verhofstad
authors.forename: L J
authors.initials: LJ
authors.lastname: Hofland
authors.forename: R R
authors.initials: RR
authors.lastname: de Krijger
authors.forename: P J
authors.initials: PJ
authors.lastname: Slootweg
authors.forename: F C S
authors.initials: FC
authors.lastname: Ramaekers
authors.forename: E-J M
authors.initials: EJ
authors.lastname: Speel
mesh_terms: D000328:Adult; D043171:Chromosomal Instability / Q000235:genetics*; D003937:Diagnosis, Differential; D005260:Female; D006801:Humans; D007340:Insulinoma / Q000175:diagnosis* / Q000235:genetics / Q000473:pathology; D008297:Male; D008875:Middle Aged; D009154:Mutation; D009362:Neoplasm Metastasis; D009693:Nucleic Acid Hybridization; D010190:Pancreatic Neoplasms / Q000175:diagnosis* / Q000235:genetics / Q000473:pathology; D011379:Prognosis; D011518:Proto-Oncogene Proteins / Q000235:genetics*
chemical_list: C105373:MEN1 protein, human; D011518:Proto-Oncogene Proteins